Artal Group S.A. Blueprint Medicines Corp Call Options Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $4.81 Million - $8.22 Million	100,000 Added 100.0%	200,000 $11.7 Million
Q4 2019 Feb 13, 2020	SELL	$66.73 - $82.59 $6.67 Million - $8.26 Million	-100,000 Reduced 50.0%	100,000 $8.01 Million
Q2 2018 Aug 10, 2018	BUY	$60.96 - $101.18 $9.14 Million - $15.2 Million	150,000 Added 300.0%	200,000 $12.7 Million
Q1 2018 May 10, 2018	BUY	$73.28 - $102.95 $3.66 Million - $5.15 Million	50,000 New	50,000 $4.59 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.